Pirfenidone
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317114

CAS#: 53179-13-8

Description: Pirfenidone is an anti-fibrotic drug for the treatment of idiopathic pulmonary fibrosis (IPF). It works by reducing lung fibrosis through downregulation of the production of growth factors and procollagens I and II. Pirfenidone has well-established antifibrotic and anti-inflammatory properties in various in vitro systems and animal models of fibrosis. A number of cell-based studies have shown that pirfenidone reduces fibroblast proliferation, inhibits TGF-β stimulated collagen production and reduces the production of fibrogenic mediators such as TGF-β.


Chemical Structure

img
Pirfenidone
CAS# 53179-13-8

Theoretical Analysis

MedKoo Cat#: 317114
Name: Pirfenidone
CAS#: 53179-13-8
Chemical Formula: C12H11NO
Exact Mass: 185.08406
Molecular Weight: 185.22
Elemental Analysis: C, 77.81; H, 5.99; N, 7.56; O, 8.64

Price and Availability

Size Price Availability Quantity
200.0mg USD 70.0 Same day
500.0mg USD 150.0 Same day
1.0g USD 250.0 Same day
2.0g USD 450.0 Same day
5.0g USD 750.0 Same day
10.0g USD 950.0 Same day
20.0g USD 1350.0 Same day
100.0g USD 1850.0 Same day
Click to view more sizes and prices
Bulk inquiry

Synonym: AMR69; AMR-69; AMR 69; Pirfenidone; brand name: Pirespa; Pirfenex; Deskar, Esbriet; Etuary.

IUPAC/Chemical Name: 5-methyl-1-phenyl-2-(1H)-pyridone

InChi Key: ISWRGOKTTBVCFA-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3

SMILES Code: O=C1C=CC(C)=CN1C2=CC=CC=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 185.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015 Mar;24(135):58-64. doi: 10.1183/09059180.00011514. Review. PubMed PMID: 25726556.

2: Poletti V, Ravaglia C, Tomassetti S. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2014 Oct;8(5):539-45. doi: 10.1586/17476348.2014.915750. Epub 2014 Aug 12. Review. PubMed PMID: 25113033.

3: Avila G, Osornio-Garduño DS, Ríos-Pérez EB, Ramos-Mondragón R. Functional and structural impact of pirfenidone on the alterations of cardiac disease and diabetes mellitus. Cell Calcium. 2014 Nov;56(5):428-35. doi: 10.1016/j.ceca.2014.07.008. Epub 2014 Jul 23. Review. PubMed PMID: 25108569.

4: Takeda Y, Tsujino K, Kijima T, Kumanogoh A. Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis. Patient Prefer Adherence. 2014 Mar 21;8:361-70. doi: 10.2147/PPA.S37233. eCollection 2014. Review. PubMed PMID: 24711695; PubMed Central PMCID: PMC3968083.

5: Kreuter M. Pirfenidone: an update on clinical trial data and insights from everyday practice. Eur Respir Rev. 2014 Mar 1;23(131):111-7. doi: 10.1183/09059180.00008513. Review. PubMed PMID: 24591668.

6: Xaubet A, Serrano-Mollar A, Ancochea J. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opin Pharmacother. 2014 Feb;15(2):275-81. doi: 10.1517/14656566.2014.867328. Epub 2013 Dec 6. Review. PubMed PMID: 24308635.

7: Pirfenidone. First, do no harm. Prescrire Int. 2013 May;22(138):117-9. Review. PubMed PMID: 23819168.

8: Cottin V. The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Respir Res. 2013;14 Suppl 1:S5. doi: 10.1186/1465-9921-14-S1-S5. Epub 2013 Apr 16. Review. PubMed PMID: 23734908; PubMed Central PMCID: PMC3643400.

9: Potts J, Yogaratnam D. Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis. Ann Pharmacother. 2013 Mar;47(3):361-7. doi: 10.1345/aph.1R337. Epub 2013 Feb 12. Review. PubMed PMID: 23404802.

10: Hilberg O, Simonsen U, du Bois R, Bendstrup E. Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis. Clin Respir J. 2012 Jul;6(3):131-43. doi: 10.1111/j.1752-699X.2012.00302.x. Review. PubMed PMID: 22697264.

11: Azuma A. Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2012 Apr;6(2):107-14. doi: 10.1177/1753465812436663. Epub 2012 Feb 14. Review. PubMed PMID: 22333982.

12: Carter NJ. Pirfenidone: in idiopathic pulmonary fibrosis. Drugs. 2011 Sep 10;71(13):1721-32. doi: 10.2165/11207710-000000000-00000. Review. PubMed PMID: 21902295.

13: Richeldi L, du Bois RM. Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. Expert Rev Respir Med. 2011 Aug;5(4):473-81. doi: 10.1586/ers.11.52. Review. PubMed PMID: 21859266.

14: Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 2011 Jun;20(120):85-97. doi: 10.1183/09059180.00001111. Review. PubMed PMID: 21632796.

15: Maher TM. Pirfenidone in idiopathic pulmonary fibrosis. Drugs Today (Barc). 2010 Jul;46(7):473-82. doi: 10.1358/dot.2010.46.7.1488336. Review. Erratum in: Drugs Today (Barc). 2014 Feb;50(2):203. PubMed PMID: 20683502.

16: Azuma A. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2010 Jun;4(3):301-10. doi: 10.1586/ers.10.32. Review. PubMed PMID: 20524912.

17: Cho ME, Kopp JB. Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. Expert Opin Investig Drugs. 2010 Feb;19(2):275-83. doi: 10.1517/13543780903501539. Review. PubMed PMID: 20050822; PubMed Central PMCID: PMC3058482.

18: Antoniu SA. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opin Investig Drugs. 2006 Jul;15(7):823-8. Review. PubMed PMID: 16787145.

19: Dosanjh A. Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients. Eur J Pharmacol. 2006 May 1;536(3):219-22. Epub 2006 Mar 14. Review. PubMed PMID: 16581063.

20: Lasky J. Pirfenidone. IDrugs. 2004 Feb;7(2):166-72. Review. PubMed PMID: 15057662.